Amicus Therapeutics (FOLD) is the lead sponsor of 7 active clinical trials listed on ClinicalTrials.gov[2], including 4 Phase 3[1].
Trial NCT06904261[3] evaluates Migalastat HCl 20 mg in Fabry Disease with a target enrollment of 8 participants. Trial NCT03911505[4] evaluates Cipaglucosidase Alfa in Pompe Disease (Late-onset) with a target enrollment of 21 participants. Trial NCT04808505[5] evaluates Cipaglucosidase alfa in Glycogen Storage Disease Type II Infantile Onset with a target enrollment of 36 participants.
No Form 4 insider filings for FOLD were recorded at the SEC in the past 30 days[6].